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Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We
investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk,
using data from 3,057 matched case–control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC).
We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass
spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a
statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate
cancer risk (OR1SD) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite
patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized
by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR1SD = 0.77, 95% confidence interval
0.66–0.89), acylcarnitines C18:1 and C18:2, glutamate, ornithine and taurine (OR1SD = 0.72, 0.57–0.90), or
lysophosphatidylcholines (OR1SD = 0.81, 0.69–0.95) had lower risk of advanced stage prostate cancer at diagnosis, with no
evidence of heterogeneity by follow-up time. Similar associations were observed for the two former patterns with aggressive
disease risk (the more aggressive subset of advanced stage), while the latter pattern was inversely related to risk of prostate
cancer death (OR1SD = 0.77, 0.61–0.96). No associations were observed for prostate cancer overall or less aggressive tumor
subtypes. In conclusion, metabolite patterns may be related to lower risk of more aggressive prostate tumors and prostate
cancer death, and might be relevant to etiology of advanced stage prostate cancer.
What’s new?
This prospective study is the largest investigation of metabolite profile and prostate cancer risk, to date. We found that patterns in
plasma metabolite profile (characterized by higher concentrations of phosphatidylcholines and hydroxysphingomyelins; specific
acylcarnitines, amino acids and a biogenic amine; and lysophosphatidylcholines, respectively) were associated with subsequent
lower risk of more aggressive tumor subtypes and prostate cancer death. Moreover, the results suggest that metabolite profile may
be relevant to the etiology of advanced stage disease.
Introduction
Prostate cancer is the second most commonly diagnosed cancer in
menworldwide, but few risk factors have been established.1,2 Using
metabolomics, which measures large numbers of small molecules
in body fluids reflecting internal (the genome, epigenome, trans-
criptome and proteome) and external factors (diet, lifestyle, envi-
ronment and gut microbiota),3–5 may help to identify novel risk
factors for prostate cancer. Previously, relatively small prospective
studies (ncases = 74–1,077), including our study in the European
Prospective Investigation into Cancer and Nutrition (EPIC),6
showed that men with higher circulating concentrations of lipids
and/or energy-relatedmetabolitesmight have lower risk of prostate
cancer, especially more aggressive tumor subtypes.6–9 Moreover,
a prospective study of lethal prostate cancer reported associations
with metabolites in redox (inverse), dipeptide (positive), pyrimi-
dine (mostly positive) and gamma-glutamyl amino acid (posi-
tively) pathways (ndeaths = 523).
10 These studies mostly had
limited power and have primarily investigated individual metab-
olites, which do not capture patterns in the metabolite profile
reflecting correlations among metabolites11; such patterns might
represent metabolites which are part of the same metabolic path-
way12 or originating from the same dietary sources.13 To over-
come this and the issue of multiple testing, dimension-reduction
methods such as treelet transform can be applied. Treelet trans-
form combines features from principal component analysis
(PCA) and cluster analysis to describe latent patterns in the data,
which often are easier to interpret than those of PCA because
metabolites irrelevant to the pattern are omitted. Treelet trans-
form has for example been used to successfully describe patterns
in serum metabolite profile12 and to identify patterns in plasma
fatty acids which were related to subsequent prostate cancer.14
We report an extension of our previous case–control study
nested in EPIC (ncase = 1,077),
6 now including 3,057 matched
case–control sets, which, to the best of our knowledge, is the
largest study to date of metabolites and prostate cancer risk.
We aimed to identify patterns in plasma metabolite profiles in
men without prostate cancer using treelet transform and to
estimate the prospective associations between patterns and sub-
sequent risk of prostate cancer overall, and by tumor character-
istics and time to diagnosis, and risk of prostate cancer death.
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The EPIC study includes 153,400 men recruited between 1992
and 2000 from 19 centers in eight countries (Denmark, Germany,
Greece, Italy, Netherlands, Spain, Sweden and United Kingdom).15
At recruitment, detailed information was collected on diet and
lifestyle, and 139,600 men gave a blood sample. For the current
study, men were eligible if they had blood stored at the central
biobank at the International Agency of Research on Cancer,
Lyon, France (IARC; centers in Germany, Greece, Italy,
Netherlands, Spain and United Kingdom), the date of blood
collection was known, and if no cancer (except non-melanoma
skin cancer) had been diagnosed at the time of blood collec-
tion. All participants gave written informed consent and the
study was approved by ethical committees of IARC and the
participating centers.
Follow-up and case and control selection
In most study centers, information on cancer incidence, tumor
subtypes and vital status was obtained via record linkage to
regional and national cancer registries. However, in Germany
and Greece, a combination of methods was used, including health
insurance records, cancer and pathology registries and active
follow-up; self-reported incident cancers were verified through
medical records.
Cases were men diagnosed with prostate cancer (defined as
code C61 in the 10th revision of the International Statistical Clas-
sification of Diseases and Related Health Problems [ICD-10])
after blood collection and before the end of follow-up in August
2014. Each case was matched on the study center, length of
follow-up and age (6 months), time of day (1 hr) and fasting
status (<3, 3–6, >6 hr) at blood collection to one control partici-
pant, selected randomly among male cohort participants who
were alive and free of cancer (except non-melanoma skin cancer)
at the time of diagnosis of the case; an incidence density sampling
procedure was used.
Prostate cancer subtypes were categorized based on the tumor-
node-metastasis (TNM) system and histological grade as follows.
Localized (≤T2 and N0/x and M0, or stage coded as localized,
n = 1,306), advanced (T3–4 and/or N1–3 and/or M1, or coded as
advanced, n = 580), non-aggressive (≤T3 and N0/x and M0,
n = 1,519), aggressive (a subset of advanced stage disease defined
as T4 and/or N1–3 and/or M1, n = 367), low-intermediate grade
(Gleason score <8 or coded as well, moderately or poorly differen-
tiated tumors, n = 2,157) and high grade (Gleason score ≥8 or
coded as undifferentiated tumors, n = 317). Death from prostate
cancer was defined as prostate cancer listed as the underlying cause
of death on the death certificate during follow-up (n = 326).
Blood collection and laboratory analysis
A standardized protocol for blood collection and processing was
followed and fasting was not required (details published else-
where15). All plasma samples (citrate anticoagulant) were assayed at
IARC, using the AbsoluteIDQ p180 Kit (Biocrates Life Sciences AG,
Innsbruck, Austria) and following the procedure recommended by
the vendor. Samples from matched case–control sets were assayed
in the same analytical batch alongwith quality control samples from
pooled plasma; laboratory personnel was blinded to sample cate-
gory, that is, case, study control or quality control. A triple quadru-
pole mass spectrometer (Triple Quad 4500; AB Sciex, Framingham,
MA) was used to quantify 148 metabolites. After exclusions of
metabolites and men, 3,057 matched case–control sets had data for
119 metabolites (details in Supporting Information Methods and
Table S1). The metabolites comprised 8 acylcarnitines, 21 amino
acids, 5 biogenic amines, 72 phosphatidylcholines (lysophosphati-
dylcholines [lysoPC, n = 8], diacyl phosphatidylcholines [PC aa,
n = 31] and acyl-alkyl phosphatidylcholines [PC ae, n = 33]), hex-
ose and 12 sphingomyelins (denoted hydroxysphingomyelins [SM
(OH), n = 5] and sphingomyelins [SM, n = 7]). See Supporting
InformationMethods formetabolite nomenclature.
Statistical analyses
Patterns in metabolite profile were identified using treelet trans-
form as described by Gorst-Rasmussen et al.16,17 In brief, treelet
transform is a data-driven linear dimension-reduction method,
which produces orthogonal components (vectors) from variables,
for example, metabolites, based on their correlation or covariance
structure. The numeric size of a variable within the component is
called the loading and quantifies the contribution of each variable
(here metabolite) to the component. A key aspect of treelet trans-
form is its sparsity feature whereby loadings for some variables
irrelevant to a given component are set to zero; this simplifies the
interpretation of the patterns.
In treelet transform, the twomost closely correlatedmetabolites
are joined together by local PCA and the two original variables are
replaced with the first principal component. This procedure is
repeated until all variables are joined into one and the structure of
the data is visualized by a cluster tree (Fig. 1). To obtain the treelet
components the cluster tree is cut at a level providing a good trade-
off between maximizing both the variance explained (higher cut-
level) and the sparsity of the components (lower cut-level); the
optimal cut-level for a given number of retained components is
determined by data-driven cross-validation. Finally, for each
retained component, a score variable is calculated as the linear
combination of a participant’s concentrations of the metabolites
weighted by the loadings. The score reflects how similar a partici-
pant’s metabolite profile is to themetabolite pattern.
In the current study, treelet transformwas based on control par-
ticipants only using the covariance matrix of logarithmically trans-
formedmetabolite concentrations. To inform the choice of number
of factors to retain and the corresponding cut-level, we ran treelet
transform for different numbers of retained components (1–10),
identified the optimal cut-level for each (ranging from 97 to 104)
using cross-validation, inspected scree plots (Supporting Informa-
tion Fig. S1)17 and assessed pattern interpretability.18 The final
treelet transform was then computed specifying the number of
components to retain and the lowest optimal cut-level. Finally,
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component scores were calculated for all participants. A sensitivity
analysis of the cut-level and a stability assessment of the treelet com-
ponents were performed.
We used conditional logistic regression to estimate risk of
prostate cancer for quintiles of component scores and per one
SD increase in component score. The analysis was conditioned
on the matching variables and further adjusted for exact age
at blood collection (continuously), baseline values of body
mass index (quartiles; unknown), smoking (never, past, cur-
rent and unknown), alcohol intake (<10, 10–19, 20–39 and
Figure 1. Cluster tree from treelet transform on 119 metabolite concentrations. The dotted line indicates the cut-level at 97. Blue lines
indicate joining of correlated metabolites which belong to the three retained treelet components (TC). n = 3,057 control participants
from EPIC.
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≥40 g of alcohol/day; unknown), attained education level
(primary, secondary, degree level and unknown) and marital
status (married or cohabiting, not married or cohabiting,
and unknown).
Similar conditional logistic regression models were fitted
for subgroup analyses by tumor subtypes (localized/advanced,
non-aggressive/aggressive and high/low-intermediate grade),
and likelihood ratio tests for heterogeneity in the association
by subtypes were conducted. To assess potential presence of
reverse causation in the associations of metabolite patterns
with risk of more aggressive prostate cancer stages, the ana-
lyses for advanced and aggressive prostate cancer were further
stratified by time to diagnosis (≤10/>10 years). In the analysis
of risk of prostate cancer death, matched sets in which the
control died, emigrated or was lost to follow-up before the
case died were excluded (n = 29).
In a sensitivity analysis, the models examining the associa-
tion between any treelet component and risk were additionally
adjusted for any other treelet components (as continuous vari-
ables) with a Pearson correlation higher than 0.2 in absolute
value with the treelet component of interest.
As a secondary analysis, we repeated the analysis of treelet
components and risk of overall prostate cancer in the subset
of participants, who were not included in our previously pub-
lished analysis (ncase = 2,018).
6
For comparison with the treelet transform method, we
additionally identified metabolite patterns using PCA and
assessed their association with risk of prostate cancer, in the
entire study population.
For the purpose of comparison with previous studies, we
also computed the associations of each individual metabolite
and risk of prostate cancer, while accounting for multiple test-
ing. This analysis was done for the full data set (ncase = 3,057),
and separately for the data not previously published6
(ncase = 2,018).
All tests of statistical significance were two-sided, and 0.05
was considered as the nominal level for statistical significance
in analyses of metabolite patterns and prostate cancer risk. All
analyses were conducted in Stata Statistical Software Package,
version 15 (Stata Corporation, College Station, TX). The “tt”
add-on for STATA is available from http://www.gorst.dk. See
Supporting Information Methods for further details of statisti-
cal analyses.
Results
At blood collection, participants were on average 58 years old
(SD = 7.3 years) and cases were diagnosed on average 9.4 years
later. There were no marked differences between baseline
characteristics of the cases and controls (Table 1).
Treelet patterns in metabolite profile
After inspection of scree plots from treelet transform
(Supporting Information Fig. S1) and cross-validation results,
we retained three patterns at cut-level 97; the hierarchical
grouping of metabolites is shown in Figure 1. Together, the three
patterns explained 31.4% of the total variation in metabolite con-
centrations, with the first to the third pattern (treelet components
1–3) accounting for 21.5, 5.2 and 4.7%, respectively (Supporting
Information Table S2). Treelet component 1 was characterized by
positive loadings on all diacyl and acyl-alkyl phosphatidylcholines
and three hydroxysphingomyelins (Fig. 2; Supporting Information
Table S2). Treelet component 2 was characterized by strong, posi-
tive loadings on acylcarnitines C18:1 and C18:2, amino acids glu-
tamate and ornithine, and biogenic amine taurine. On treelet
component 3, all eight lysophosphatidylcholines loaded strongly,
positively. There was a positive correlation between treelet com-
ponents 1 and 3 (r = 0.46), while treelet component 2 was not
strongly correlated with the other patterns (Supporting Informa-
tion Table S3).
Treelet patterns and prostate cancer risk
Associations of metabolite patterns and risk of prostate cancer
are shown in Figure 3 and Supporting Information Table S4.
No associations were observed for prostate cancer overall, nor
with localized, non-aggressive, low-intermediate and high
grade prostate cancer.
Treelet component 1 was inversely associated with risk of
advanced stage prostate cancer (odds ratio for a SD increase
in treelet component score [OR1SD] = 0.77, 95% confidence
interval [CI] 0.66–0.89, p = 0.0007), suggesting that men with
higher concentrations of diacyl and acyl-alkyl phosphatidyl-
cholines and three hydroxysphingomyelins had a lower risk of
advanced stage prostate cancer (Fig. 3 and Supporting Infor-
mation Table S4). The results were unchanged when stratify-
ing at 10 years of follow-up. Furthermore, treelet component
1 was associated with risk of aggressive prostate cancer
(OR1SD = 0.79, 95%CI 0.66–0.95, p = 0.013), with no hetero-
geneity by follow-up time. In the sensitivity analysis further
adjusting for treelet component 3, results for treelet compo-
nent 1 remained largely unchanged, although the associations
with advanced stage with more than 10 years of follow-up and
with aggressive prostate cancer were slightly attenuated and
no longer statistically significant (Supporting Information
Table S5).
Men who scored higher on treelet component 2, character-
ized by higher acylcarnitines C18:1 and C18:2, glutamate,
ornithine and taurine, had a lower risk of advanced stage dis-
ease (OR1SD = 0.72, 95%CI 0.57–0.90, p = 0.005; Figure 3 and
Supporting Information Table S4). When stratifying by
follow-up time, risk estimates remained unchanged, but the
significance was borderline for follow-up beyond 10 years
(OR1SD = 0.70, 95%CI 0.48–1.02, p = 0.066), perhaps due to
lower numbers. Moreover, this pattern was inversely associ-
ated with risk of aggressive prostate cancer (OR1SD = 0.70,
95%CI 0.53–0.93, p = 0.014), with no heterogeneity by follow-
up time.
Treelet component 3, characterized by positive loadings on
lysophosphatidylcholines, was inversely related to risk of
724 Metabolite profile and prostate cancer risk












advanced stage prostate cancer (OR1SD = 0.81, 95%CI 0.69–0.95,
p = 0.009; Figure 3 and Supporting Information Table S4). Risk
estimates were similar when stratifying by time to diagnosis and
remained significant for follow-up beyond 10 years (OR1SD =
0.76, 95%CI 0.60–0.97, p = 0.030). An inverse association with
risk of death from prostate cancer was also observed (OR1SD =
0.77, 95%CI 0.61–0.96, p = 0.023). When further adjusting for
treelet component 1, the associations of treelet component 3 with
advanced prostate cancer were slightly attenuated and no longer
statistically significant, while the association with prostate cancer
death remained (Supporting Information Table S5).
When restricting the analysis to 2,018 cases and their mat-
ched controls who were not included in our previous
publication,6 we obtained similar results to those observed for
the full study population (ncase = 3,057; Supporting Informa-
tion Table S6).
Principal component analysis
Treelet components 1 and 2, were similar to principal components
1 (r = 0.99) and 2 (r = 0.88), respectively (Supporting Informa-
tionTables S7 and S8). Treelet component 3 (lysophosphatidylcholines)
was correlated with principal components 1 (r = 0.54), 5 (r = 0.43)
and 9 (r = 0.38) but qualitatively most similar to principal compo-
nent 9, which was mostly characterized by positive loadings on the
lysophosphatidylcholines, some acylcarnitines (especially C14:1),
amino acids arginine and t4-hydroxyproline, and sphingomyelin
SMC20:2, while having negative loadings on amino acid glutamate
and several phosphatidylcholines.
The associations of principal components 1 and 2 with
prostate cancer risk (Supporting Information Table S9) were
similar to those observed for treelet components 1 and
2 (Fig. 3), respectively. Unlike treelet component 3, principal
component 9 was not associated with advanced stage prostate
cancer, but in line with the main results, a trend toward an
inverse association with risk of prostate cancer death was
observed (OR1SD = 0.85, 95%CI 0.0.70–1.03, p = 0.095). Prin-
cipal component 1 was inversely associated with risk of
advanced (overall and by follow-up time) and aggressive pros-
tate cancer (with no heterogeneity by length of follow-up), but
not prostate cancer death, while principal component 5 was
not related to risk of any prostate cancer outcome.
In addition, principal component 4, characterized by positive
loadings on several acylcarnitines, amino acid t4-hydroxyproline,
biogenic amine sarcosine and several phosphatidylcholines, and
inverse loadings on other phosphatidylcholines and sphingolipids,
was inversely associated with advanced (with no heterogeneity by
follow-up time), aggressive (with a somewhat stronger association
in men who had been followed up for more than 10 years) and
high grade prostate cancer. Finally, principal component 8, mainly
characterized by positive loadings on some acylcarnitines, arginine,






Age at blood collection, years (SD) 58.0 (7.3) 58.0 (7.3)
Height, cm (SD)1 172.2 (7.0) 172.4 (7.1)
Body Mass Index, kg/m2 (SD)1 27.2 (3.4) 27.2 (3.5)
Smoking, n (%)1
Never 1,031 (34.3) 938 (31.1)
Former 1,276 (42.4) 1,316 (43.6)
Current 703 (23.4) 765 (25.3)
Alcohol consumption, n (%)1
<10 g/day 1,271 (41.7) 1,272 (41.6)
10–19 g/day 577 (18.9) 577 (18.9)
20–40 g/day 632 (20.7) 674 (22.1)
≥40 g/day 566 (18.6) 533 (17.4)
Physical activity, n (%)1
Inactive 710 (23.7) 721 (24.1)
Moderately inactive 986 (33.0) 985 (32.9)
Moderately active 716 (23.9) 698 (23.3)
Active 579 (19.4) 592 (19.8)
Marital status, n (%)1
Married or cohabiting 2,051 (88.5) 2,063 (88.9)
Not married or cohabiting 267 (11.5) 257 (11.1)
Educational attainment, n (%)1
Primary or equivalent 1,181 (40.6) 1,195 (40.9)
Secondary 1,001 (34.4) 1,026 (35.1)
Degree 727 (25.0) 704 (24.1)
Cases only
Age at diagnosis, years (SD)1 67.4 (6.9) –
Time to diagnosis, years (SD)1,2 9.4 (4.2)
Stage, n (%)1,3
Localized 1,306 (69.2) –
Advanced 580 (30.8) –
Stage (aggressiveness), n (%)1,3
Non-aggressive 1,519 (80.5) –
Aggressive 367 (19.5) –
Grade, n (%)1,4
Low-intermediate grade 2,157 (87.2) –
High grade 317 (12.8) –
Death from prostate cancer, n (%)1,5 297 (9.7) –
1Unknown values for some participants; the calculations of percentages
exclude missing values.
2Time between blood collection and diagnosis.
3The tumor-node-metastasis (TNM) system was used to categorize stages of
prostate cancer; localized: ≤T2 and N0/x and M0, or coded as localized;
advanced: T3–4 and/or N1–3 and/or M1, or coded as advanced; non-aggressive:
≤T3 and N0/x and M0; and aggressive: T4 and/or N1–3 and/or M1. All categories
are notmutually exclusive as aggressive is a subset of advanced stage, so num-
bers do not add up; percentages were calculated separately for localized and
advance, and for non-aggressive and aggressive.
4Gleason score <8 or coded as well, moderately or poorly differentiated for
low-intermediate grade and Gleason score ≥8 or coded as undifferentiated
for high grade.
5Death from prostate cancer (prostate cancer listed as the underlying
cause of death on the death certificate) during follow-up; 326 died from
prostate cancer, but 29 were excluded from further analysis as their mat-
ched control either died, emigrated or was lost to follow-up before
they died.
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t4-hydroxyproline and SM C20:2, mixed loadings on the glyce-
rophospholipids, and inverse loadings on all the hydrox-
ysphingomyelins, was inversely associated with all prostate cancer
outcomes, except advanced prostate cancer at longer follow-up
and prostate cancer death.
Analysis of individual metabolites
Results of the associations between individual metabolite concen-
trations and prostate cancer risk in the full dataset (ncase = 3,057)
and in the data not previously published6 (ncase = 2,018) are
shown in Supporting Information Tables S10–S23. Results from
the new dataset were in line with those of the full dataset,
although slightly weaker, with two obvious exceptions; acyl-
alkyl phosphatidylcholines were more often associated with
overall prostate cancer in the new dataset than in the full dataset
(Supporting Information Tables S10 and S17), and the same
was the case for diacyl phosphatidylcholines and risk of low-
intermediate grade prostate cancer (Supporting Informa-
tion Tables S15 and S22).
Discussion
In this large prospective study, treelet transform identified three
easily interpretable patterns in men’s metabolite profile. We
observed a lower risk of advanced stage prostate cancer among
men with metabolite profiles akin to those described by treelet
components 1 and 2, characterised by higher concentrations of
phosphatidylcholines and hydroxysphingomyelins (treelet com-
ponent 1), or the combination of acylcarnitines C18:1 and C18:2,
glutamate, ornithine and taurine (treelet component 2). Impor-
tantly for our understanding of potential etiological factors for
prostate cancer, the risk estimates remained similar in case-sets in
which the case was diagnosed more than 10 years after blood col-
lection. These twometabolite patterns showed similar associations
with aggressive prostate cancer (the more aggressive subset of
advanced stage prostate cancer), also with no heterogeneity by
follow-up time. Moreover, similar results were observed for men
with higher concentrations of lysophosphatidylcholines (treelet com-
ponent 3) but these associations were partly explained by con-























































Figure 2. Loading plots for treelet components 1, 2 and 3 from treelet transform on 119 metabolite concentrations, using cut-level 97. The
loading is the numeric size of a metabolite within the component, and it quantifies the contribution of each metabolite to the component.
n = 3,057 control participants from EPIC.
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pattern (treelet component 1), while the association of treelet compo-
nent 3 with prostate cancer death may be independent of treelet
component 1.
To the best of our knowledge, only one other prospective
study of metabolites and prostate cancer risk has applied
dimension-reduction methods to the full set of metabolites. None
of 10 metabolite patterns derived using PCA were related to risk
of overall or aggressive prostate cancer (defined by combining
stage and grade information) in observational analyses within
the Prostate, Lung, Colorectal and Ovarian Cancer Screening
Trial; 695 metabolites measured using mass spectrometry
were included, but the metabolites which characterized each
pattern were not described.19 Use of different metabolomics
platforms, dimension-reduction methods, study populations
and tumor subtype categorization may partly explain the dif-
ferences in results.
The clustering of phosphatidylcholine and sphingomyelins
(treelet component 1) as well as the positive correlation
between treelet components 1 and 3 (lysophosphatidylcholines)
observed here may be explained by shared metabolic pathways;
sphingomyelins are synthesized from phosphatidylcholines,20
and lysophosphatidylcholines are a subtype of phosphatidyl-
cholines with one fatty acid side chain. In line with our results,
treelet transform applied to untargeted metabolomics and
lipidomics data from EPIC-Potsdam also identified a pattern
characterized by positive loadings on a sphingomyelin, three
phosphatidylcholines and other glycerophospholipids12 (a class
including phosphatidylcholines21). Diet, fitness level, alcohol
intake and body mass index might be modifiable determinants
of these metabolites.22–26
The current results on phosphatidylcholines and sphingomyelins
(treelet component 1) and risk are broadly consistent with those of
other prospective studies investigating individual metabolites,
including our previously published results,6 which were conducted
in a subset (~35%) of the current study population. For example, we
previously reported inverse associations of many individual phos-
phatidylcholines, all of which were included with positive loadings
in treelet component 1 or 3, with risk of advanced stage prostate can-
cer, and some associations remained when restricting the analysis to
aggressive prostate cancer. We observed generally similar but less
strong associations when restricting the analysis to just the new data
included in the current analysis. Comparisonwith results from other
Figure 3. Odds ratio of prostate cancer overall and subgroups associated with a one standard deviation increase in treelet component scores.
Stage and grade of prostate cancer were categorized using the tumor-node-metastasis (TNM) system and Gleason score, respectively;
localized (≤T2 and N0/x and M0, or stage coded as localized), advanced (T3–4 and/or N1–3 and/or M1, or coded as advanced), non-aggressive
(≤T3 and N0/x and M0), aggressive (a subset of advanced stage disease defined as T4 and/or N1–3 and/or M1), low-intermediate grade
(Gleason <8 or coded as well, moderately or poorly differentiated tumors) and high grade (Gleason ≥8 or coded as undifferentiated tumors).
Death from prostate cancer during follow-up was defined as prostate cancer listed as the underlying cause of death on the death certificate.
One matched set was excluded from the analysis of aggressive prostate cancer with follow-up >10 years; the case was the only individual
with unknown smoking status in this subgroup and the model was thus not stable. Abbreviations: OR1SD, odds ratio for a one standard
deviation increase in treelet component score; CI, confidence interval; yrs, years; PrCa, prostate cancer.
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studies is complex because of the use of different analytical
platforms, for which only a limited number of metabolites
(acylcarnitines, amino acids and biogenic amines) perfectly
overlap with the metabolites studied here, and of a different
classification of prostate cancer subtypes (aggressive prostate
cancer was defined by combining information on stage and
grade, in previous publications from other groups). Nonethe-
less, observational analyses within the Alpha-Tocopherol,
Beta-Carotene Cancer Prevention Study (ATBC) found that
men with higher concentrations of some glycerophospholipids
had lower risk of aggressive prostate cancer8 and possibly
tumor stage T327; these results appear similar to our findings.
In contrast, little is known about the association of
lysophosphatidylcholines (treelet component 3) with risk of
dying from prostate cancer. Another study in ATBC reported
an inverse association between lysolipid 1-linoleoyl-
glycerophosphatidylcholine (18:2), which is comparable to
lysoPC a C18:2 included in TC3 of the current study, and risk
of death from prostate cancer (ndeaths = 523),
10 but death was
not an outcome in the other previous papers.
The metabolite classes included in treelet components 1 and
3 are structural components of cell membranes, and along with
the related enzymes and intermediates they are involved in prolif-
eration, cell signaling and cell survival, and thusmay play key roles
in carcinogenesis, progression and migration of tumors.20,21,28
Their potential association may apply to cancer in general rather
than being prostate cancer-specific; some prospective studies have
reported lower risk of breast cancer,9,29 colorectal cancer,30 hepa-
tocellular carcinoma31,32 and pancreatic cancer33 in relation to
higher levels of phosphatidylcholines and related metabolites,
while another study did not observe an association between the
few included phospholipids and breast cancer risk.34
Involvement in shared metabolic pathways may also explain the
grouping of metabolites in treelet component 2. Acylcarnitines are
involved in β-oxidation of fatty acids, which produces acetyl coen-
zyme A for energy production via the Krebs cycle.35 Glutamate also
feeds into this cycle by conversion to α-ketoglutarate but can also be
converted to ornithine. Moreover, taurine has been proposed to
stimulate β-oxidation and support mitochondrial function.36 Thus,
alteration in energy metabolism could be one possible underlying
mechanism of the observed associations between treelet component
2 and reduced risk of advanced stage and aggressive prostate
cancer. In line with our results, analyses in ATBC showed an
inverse association between metabolites related to energy metabo-
lism (α-ketoglutarate and citrate) and risk of aggressive prostate
cancer.7,8 Our previous study in EPIC also suggested inverse associ-
ations of acylcarnitines and taurine with advanced prostate cancer.6
There are also some published data on dietary and lifestyle corre-
lates of themetabolites in treelet component 2.23,26,37,38
Altered levels of phosphatidylcholines, lysophospholipids
(mostly lower), sphingomyelins, acylcarnitines, glutamate, orni-
thine (mostly lower) and taurine in postdiagnostic samples from
prostate cancer patients have been reported.4,39,40 The most recent
of these studies, used Mendelian randomization to assess the
causality of cross-sectionally observed associations between
14 serum metabolites (including tyrosine), measured using
nuclearmagnetic resonance spectroscopy, and overall risk of pros-
tate cancer, detected via prostate-specific antigen test.40 No associ-
ations between genetic markers of these metabolites (explaining a
median of 6.8% [range 0.4–11.2%] of the variance in metabolite
concentrations41) and risk of prostate cancer were observed.40
This suggests no evidence of causality in the associations between
these specific metabolites and risk of prostate cancer overall. While
these case–control studies could imply that our resultsmay be driven
by tumors already present at blood collection, our prospective analy-
sis excluding the first 10 years of follow-up suggests that differences
in metabolite concentrations may precede carcinogenesis and thus
potentially be relevant for the etiology of prostate cancer.
This study benefits from the large, mature and well-described
cohort, which provided more statistical power than previous
papers, and limited potential reverse causation and confounding.
Additionally, treelet transform was applied to reduce issues of
multiple testing and correlated variables pertaining to univariate
analyses, while producing interpretable and stable metabolite pat-
terns. For comparison, we also derive metabolite patterns using
the more common PCA, and associations of the first and second
principal components with prostate cancer risk were similar to
those of the first and second treelet components, respectively. The
advantage of treelet transform for analysis of metabolomics data
in epidemiological studies has further been highlighted by a study
also observing that treelet components were similar to and easier
to interpret than components from PCA, albeit with somewhat
less variance explained.12 A limitation of treelet transform is the
need to select a cut-level to produce components. However, the
choice is aided by data-driven cross-validation, and the sensitivity
analysis of the cut-level produced similar components.
Further limitations of this study are related to the blood
sampling, handing and assay procedure. Only one blood sam-
ple was available per participant, which may lead to attenua-
tion of risk estimates if a single measurement does not
represent long-term exposure. Although studies of short-term
reproducibility suggest that one measurement may be ade-
quate for most metabolites (median intercorrelation coeffi-
cients of 0.45–0.70 over 0.3–2.3 years),42–45 long-term
reproducibility is lower (mean r = 0.28, 0.13 and 0.16 over
15 years for all measured metabolites, diacyl and acyl-alkyl
phosphatidylcholines, respectively).44 Moreover, differences in
sample handling procedures between study centers and the
use of nonfasting blood samples might potentially have atten-
uated our risk estimates. To minimize this, cases and controls
were matched on study center and fasting status, and the lat-
ter has been shown to explain only a small amount of variabil-
ity in metabolite concentrations.23,46–48
In conclusion, in this the largest study to date, we found
evidence that easily interpretable patterns in baseline plasma
metabolite profile, identified using treelet transform, are asso-
ciated with subsequent risk of more aggressive prostate cancer
subtypes. Men with metabolite profiles characterized by higher
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concentrations of either phosphatidylcholines and hydrox-
ysphingomyelins, or acylcarnitines C18:1 and C18:2, gluta-
mate, ornithine and taurine, had lower risk of advanced and
aggressive stage prostate cancer. Differences in scores on these
metabolite patterns between cases and controls may precede
diagnosis of advanced stage prostate cancer by more than
10 years and thus might be relevant to further understanding
of prostate cancer etiology and prevention. Moreover, men
with metabolite profiles high in lysophosphatidylcholines may
be at lower risk of dying from prostate cancer.
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